Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis. 2008

Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
1 Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

BACKGROUND BK virus (BKV) infection of kidney transplant patients is an increasing problem and is thought to be secondary to potent immunosuppressive therapy. BKV infection progresses to BKV nephritis (BKVN) in approximately 8% of transplants and in half of these cases the graft is lost. METHODS We used an interferon-gamma enzyme-linked immunosorbent spot (ELISPOT) assay to measure the cellular immune response to peptides encoding BKV large T antigen. Eight kidney transplant patients with BKVN were tested at the time of diagnosis of BKVN and then after resolution of active BKV infection. RESULTS When total spot counts from all peptide pools were combined, the mean ELISPOT signal per 10,000 cells at the time of BKVN diagnosis was 23.1 (range 3.4-59.7), with a median of 21.8. This increased to 70.2 (range 5.4-189.4) with a median of 37.0 (P=0.1216) after resolution of active BKV infection. To further increase specificity of response, we counted the number of peptide pools with ELISPOT activity of greater than 10 spots per well after subtraction of background. The mean number of pools fitting this criteria at the time of BKVN diagnosis was 2.1 (range 0-8) with a median of 1.5; this increased to 8 (range 1-18) and a median of 6.5 after recovery (P=0.0338). CONCLUSIONS This demonstrates that recovery of cellular immune response to large T antigen corresponds with resolution of active BKV infection. This may prove useful in monitoring patients' cellular immunity and recovery from active BKV infection when treated with reduction in immunosuppressive therapy.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009393 Nephritis Inflammation of any part of the KIDNEY. Nephritides
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D001739 BK Virus A species of POLYOMAVIRUS apparently infecting over 90% of children but not clearly associated with any clinical illness in childhood. The virus remains latent in the body throughout life and can be reactivated under certain circumstances. BK polyomavirus,Human Polyomavirus BK,Polyomavirus, BK,Polyomavirus hominis 1,Polyomavirus BK, Human
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
May 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
August 2018, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation,
Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
October 1984, Virology,
Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
September 1991, Oncogene,
Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
January 2015, Frontiers in immunology,
Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
December 2008, Current opinion in organ transplantation,
Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
April 1996, Journal of virology,
Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
October 2006, The Journal of general virology,
Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
May 2020, Blood advances,
Simon E Prosser, and Rimas J Orentas, and Lisa Jurgens, and Eric P Cohen, and Sundaram Hariharan
October 1974, International journal of cancer,
Copied contents to your clipboard!